- Case-Based Roundtable
- General Dermatology
- Eczema
- Chronic Hand Eczema
- Chronic Spontaneous Urticaria
- Alopecia
- Aesthetics
- Vitiligo
- COVID-19
- Actinic Keratosis
- Precision Medicine and Biologics
- Rare Disease
- Wound Care
- Rosacea
- Psoriasis
- Psoriatic Arthritis
- Atopic Dermatitis
- Melasma
- NP and PA
- Skin Cancer
- Hidradenitis Suppurativa
- Drug Watch
- Pigmentary Disorders
- Acne
- Pediatric Dermatology
- Practice Management
- Prurigo Nodularis
- Buy-and-Bill
Quiz
Article
Dermatology Times Spot Test: May 17, 2025
Author(s):
Key Takeaways
- Remibrutinib has shown promise in treating chronic spontaneous urticaria, as evidenced by recent research findings.
- Dupixent® (dupilumab) has been approved as the first new targeted therapy for CSU in over ten years in the US.
Put your dermatology expertise to the test with Dermatology Times’ interactive quiz series!
Dermatology Times presents: Spot Test!
Each week, dive into a series of thought-provoking questions designed to test your understanding of essential topics, trends, and breakthroughs in dermatology.
This week, we’ll focus on chronic spontaneous urticaria (CSU).
Do you have a set of quiz questions to share? Contact editor Emma Andrus at eandrus@mjhlifesciences.com to contribute!
Which of the following biologics recently demonstrated rapid and sustained efficacy in patients with antihistamine-refractory CSU in the phase 3 REMIX-1 and REMIX-2 trials?
What is the mechanism of action of remibrutinib, the investigational therapy being studied for CSU?
In April 2025, the FDA approved dupilumab (Dupixent) for which patient population with CSU?
References
- Metz M, Giménez-Arnau A, Hide M, et al. Remibrutinib in chronic spontaneous urticaria. N Engl J Med. 2025;392(10):984-994. doi:10.1056/NEJMoa2408792
- Dupixent® (dupilumab) approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria (CSU). News release. Globe Newswire. April 18, 2025. Accessed May 16, 2025. https://www.globenewswire.com/news-release/2025/04/18/3064133/0/en/Dupixent-dupilumab-Approved-in-the-U-S-as-the-First-New-Targeted-Therapy-in-Over-a-Decade-for-Chronic-Spontaneous-Urticaria-CSU.html
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
